000182138 001__ 182138
000182138 005__ 20240229145710.0
000182138 0247_ $$2doi$$a10.1111/tan.14846
000182138 0247_ $$2pmid$$apmid:36251018
000182138 0247_ $$2ISSN$$a0001-2815
000182138 0247_ $$2ISSN$$a1399-0039
000182138 0247_ $$2ISSN$$a2059-2302
000182138 0247_ $$2ISSN$$a2059-2310
000182138 0247_ $$2altmetric$$aaltmetric:137318992
000182138 037__ $$aDKFZ-2022-02455
000182138 041__ $$aEnglish
000182138 082__ $$a610
000182138 1001_ $$00000-0001-6648-8828$$aWitt, Johannes$$b0$$eFirst author
000182138 245__ $$aA simple approach for detecting HLA-A*02 alleles in archival formalin-fixed paraffin-embedded tissue samples and an application example for studying cancer immunoediting.
000182138 260__ $$aOxford$$bWiley$$c2023
000182138 3367_ $$2DRIVER$$aarticle
000182138 3367_ $$2DataCite$$aOutput Types/Journal article
000182138 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1671027646_24789
000182138 3367_ $$2BibTeX$$aARTICLE
000182138 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000182138 3367_ $$00$$2EndNote$$aJournal Article
000182138 500__ $$a#EA:F210#LA:F210# / 2023 Jan;101(1):24-33
000182138 520__ $$aThe human leukocyte antigen (HLA) system represents a central component of the antigen presentation machinery. As every patient possesses a defined set of HLA molecules, only certain antigens can be presented on the cell surface. Thus, studying HLA type-dependent antigen presentation can improve the understanding of variation in susceptibility to various diseases, including infectious diseases and cancer. In archival formalin-fixed paraffin-embedded (FFPE) tissue, the HLA type is difficult to analyze due to fragmentation of DNA, hindering the application of commonly used assays that rely on long DNA stretches. Addressing these difficulties, we present a refined approach for characterizing presence or absence of HLA-A*02, the most common HLA-A allele in the Caucasian population, in archival samples. We validated our genotyping strategy in a cohort of 90 samples with HLA status obtained by an NGS-based method. 90% (n=81) of the samples could be analyzed with the approach. For all of them, the presence or absence of HLA-A*02 alleles was correctly determined with the method, demonstrating 100% sensitivity and specificity (95% CI: 91.40 to 100% and 91.19 to 100%). Furthermore, we provide an example of application in an independent cohort of 73 FFPE microsatellite-unstable (MSI) colorectal cancer samples. As MSI cancer cells encompass a high number of mutations in coding microsatellites (cMS), leading to the generation of highly immunogenic frameshift peptide (FSP) antigens, they are ideally suited for studying relations between the mutational landscape of tumor cells and interindividual differences in the immune system, including the HLA genotype. Overall, our method can help to promote studying HLA type-dependency during the pathogenesis of a wide range of diseases, making archival and historic tissue samples accessible for identifying HLA-A*02 alleles. This article is protected by copyright. All rights reserved.
000182138 536__ $$0G:(DE-HGF)POF4-316$$a316 - Infektionen, Entzündung und Krebs (POF4-316)$$cPOF4-316$$fPOF IV$$x0
000182138 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000182138 650_7 $$2Other$$aCancer immunoediting
000182138 650_7 $$2Other$$aFormalin-fixed paraffin-embedded tissue samples
000182138 650_7 $$2Other$$aHLA typing
000182138 650_7 $$2Other$$aMSI cancer
000182138 7001_ $$aHaupt, Saskia$$b1
000182138 7001_ $$0P:(DE-He78)07eef6d38a91f4642c810745c5bf5000$$aAhadova, Aysel$$b2$$udkfz
000182138 7001_ $$0P:(DE-He78)a7f54298fcba548e34453b02202e6519$$aBohaumilitzky, Lena$$b3$$udkfz
000182138 7001_ $$0P:(DE-He78)bf22847e1e57b38a1cac0e03d63dbdec$$aFuchs, Vera$$b4$$udkfz
000182138 7001_ $$0P:(DE-HGF)0$$aBallhausen, Alexej$$b5
000182138 7001_ $$0P:(DE-He78)2c6d4f81ba6891f170d25801c181ace1$$aPrzybilla, Moritz Jakob$$b6$$udkfz
000182138 7001_ $$0P:(DE-HGF)0$$aJendrusch, Michael$$b7
000182138 7001_ $$aSeppälä, Toni T$$b8
000182138 7001_ $$00000-0001-9542-3169$$aFürst, Daniel$$b9
000182138 7001_ $$aWalle, Thomas$$b10
000182138 7001_ $$aBusch, Elena$$b11
000182138 7001_ $$0P:(DE-He78)f54d0426f2215c539d3a7ae1b400b57d$$aHaag, Georg Martin$$b12$$udkfz
000182138 7001_ $$aHüneburg, Robert$$b13
000182138 7001_ $$aNattermann, Jacob$$b14
000182138 7001_ $$0P:(DE-He78)11747cd1dc061b9333c0e3a3ff31bf2f$$avon Knebel Doeberitz, Magnus$$b15$$udkfz
000182138 7001_ $$aHeuveline, Vincent$$b16
000182138 7001_ $$0P:(DE-He78)028ee60cca729028708496826f077b58$$aKloor, Matthias$$b17$$eLast author$$udkfz
000182138 773__ $$0PERI:(DE-600)2844321-4$$a10.1111/tan.14846$$gp. tan.14846$$n1$$p24-33$$tHLA$$v101$$x0001-2815$$y2023
000182138 909CO $$ooai:inrepo02.dkfz.de:182138$$pVDB
000182138 9101_ $$0I:(DE-588b)2036810-0$$60000-0001-6648-8828$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000182138 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)07eef6d38a91f4642c810745c5bf5000$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000182138 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a7f54298fcba548e34453b02202e6519$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000182138 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bf22847e1e57b38a1cac0e03d63dbdec$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000182138 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000182138 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2c6d4f81ba6891f170d25801c181ace1$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000182138 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000182138 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f54d0426f2215c539d3a7ae1b400b57d$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000182138 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)11747cd1dc061b9333c0e3a3ff31bf2f$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000182138 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)028ee60cca729028708496826f077b58$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000182138 9131_ $$0G:(DE-HGF)POF4-316$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfektionen, Entzündung und Krebs$$x0
000182138 9141_ $$y2022
000182138 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2021-01-29$$wger
000182138 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-29
000182138 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-29
000182138 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-29
000182138 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-27
000182138 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-27
000182138 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-27
000182138 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-27
000182138 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-27
000182138 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-27
000182138 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bHLA : 2022$$d2023-10-27
000182138 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-27
000182138 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-27
000182138 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bHLA : 2022$$d2023-10-27
000182138 9202_ $$0I:(DE-He78)F210-20160331$$kF210$$lKKE Angewandte Tumorbiologie$$x0
000182138 9201_ $$0I:(DE-He78)F210-20160331$$kF210$$lKKE Angewandte Tumorbiologie$$x0
000182138 9201_ $$0I:(DE-He78)D120-20160331$$kD120$$lD120 Angewandte Tumor-Immunität$$x1
000182138 9200_ $$0I:(DE-He78)F210-20160331$$kF210$$lKKE Angewandte Tumorbiologie$$x0
000182138 980__ $$ajournal
000182138 980__ $$aVDB
000182138 980__ $$aI:(DE-He78)F210-20160331
000182138 980__ $$aI:(DE-He78)D120-20160331
000182138 980__ $$aUNRESTRICTED